Drug Profile
Research programme: prophylactic vaccine - Novartis/Mutabilis
Latest Information Update: 14 Jul 2010
Price :
$50
*
At a glance
- Originator Mutabilis; Novartis
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 Jul 2010 Discontinued - Preclinical for Undefined indication in France (unspecified route)
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
- 20 Jun 2005 Preclinical trials in Undefined in France (unspecified route)